Metabolomics company

Cristina Alonso, PhD

Cristina Alonso completed a BSc degree in Chemistry from the University of Valladolid and a PhD in Analytical Chemistry. She joined OWL Metabolomics in 2007 as a Chromatography and Mass Spectrometry Specialist, and currently serves as the Services Manager and Head of the Data Processing Department. In her role, she trains Data Processing Specialists and provides technical support for the company’s R&D.

Dr. Alonso scientific career has been focused on processing and interpretation of mass spectrometry-based metabolomic data, dedicated to the search for non-invasive biomarkers for liver diseases diagnosis and drug effect in NASH clinical trials. She has contributed to over 70 scientific publications in high impact journals.

(Researcher unique identifier: https://orcid.org/0000-0002-2019-678X).

Miguel Campo

Miguel Campo has a Bachelor’s degree in Pharmacy from the Madrid Complutense University (UCM) and a Master’s degree in Sales and Marketing Management in Pharmaceutical and Related Industries. Miguel has more than 23 years of experience as a Business Development Manager in the pharmaceutical industry, in different CROs. His experience spans across multiple therapeutic areas, including Oncology, Respiratory, Cardiovascular, Haematology, Vaccines and Neurology. Miguel has joined OWL Metabolomics in 2023 as a Business Development Manager.

Toni Felís Soto

Toni Felís Soto, Bachelor of Business Administration graduate from the Universitat Autònoma de Barcelona and an Executive Masters in Finance from the ESADE Business & Law School, started his professional journey as an auditor at PricewaterhouseCoopers. In 2008, he joined Laboratorios Rubió, leading the Treasury, Accounting, and Legal departments for fourteen years. His comprehensive skillset has fostered an in-depth understanding of the pharmaceutical industry, enhancing his customer-oriented approach. Currently, he serves as the Business Unit Manager at OWL Metabolomics, leading the team of people that make up the organization.

Ibon Martinez Arranz

Ibon Martínez-Arranz, with a BSc degree in Mathematics, an MSc in Applied Statistical Techniques, and an MSc in Mathematical Modeling, joined OWL Metabolomics in 2010. Since 2017, he has been the Data Science Manager at OWL Metabolomics, overseeing prediction and statistical computing management. His team supports metabolomic services, data handling, and research and development projects. Currently, Martínez-Arranz is finalizing his doctoral thesis on the application of genetic algorithms for the selection of NAFLD subtypes.

(Researcher unique identifier: https://orcid.org/0000-0001-9483-8426).

Rebeca Mayo, PhD

Rebeca Mayo received her BSc degree in Chemistry from the University of Valladolid, where she also completed her PhD in Analytical Chemistry. In 2009 she joined OWL Metabolomics as a Chromatography and Mass Spectrometry Specialist in the Metabolomics Department. In 2012 she became part of the Management Team as Laboratory and Metabolomics Platform Manager. Since 2015, she has been the Head of Products Area, being actively involved in developing the in vitro diagnostic medical devices developed by OWL Metabolomics and their compliance with regulations.

Currently, Dr. Mayo is the Operations Manager, overseeing lab operations, R&D activities, and technology transfer processes. As one of the principal scientists at OWL Metabolomics, she is co-author of more than 20 scientific publications.

(Researcher unique identifier: https://orcid.org/0000-0001-9733-2121).

Jesús Bañales, PhD

Dr. Jesús Bañales is an Ikerbasque Research Professor and the Head of the Hepatic Diseases Group at the Biodonostia Health Research Institute – Donostia University Hospital, in San Sebastián. In addition, he is a Professor of Biochemistry at the University of Navarra (Pamplona), as well as an Associate Professor of Medicine/Sciences at Mayo Clinic (Rochester, USA) and the Universidad Área Andina (Bogotá, Colombia).

His Hepatic Diseases Research Group consists of 25 multidisciplinary researchers focused on studying the molecular mechanisms involved in liver pathophysiology and the search for new diagnostic and therapeutic strategies.

Prof. Bañales is the author of more than 200 scientific publications in high-impact journals and has led more than 50 competitive national and international research projects. He is a member of the Editorial Board of the scientific journals Hepatology, Journal of Hepatology (Associate Editor) and Nature Reviews Gastroenterology & Hepatology. He has been recognized with various international research awards, such as the EASL Emerging Leader Award 2018, UEG Rising Star Award 2018, and “SER Navarra Researcher Award” 2020.

Dina Ferreira

Dina Ferreira has a Bachelor’s and Master’s Degree in Pharmacy from the Faculdade de Farmácia da Universidade de Lisboa, a Postgraduate Degree in Laboratory Management and Auditor Training, and is coursing a PDD, Director Development Program Business Administration and Management at IESE.

Currently, she is the Chief Scientific Officer and a member of the board of directors at Laboratorios Rubió. She has robust knowledge in the pharmaceutical sector acquired over more than 17 years, which has given her great expertise in driving innovation through leadership roles and scientific research. In her current role at OWL Metabolomics, Dina’s comprehensive background will contribute to aligning the company’s R&D efforts with those of Laboratorios Rubió.

José M Mato, PhD

José M. Mato, completed his education at the Complutense University of Madrid and the University of Leiden. He conducted his research in the Netherlands, Switzerland, United States, and Spain before being appointed as Research Professor at the Spanish Council for Scientific Research (CSIC) in 1986. From 1992 to 1996, he was president of CSIC. In 2004, he received the National Prize for Research in Medicine in recognition of his contributions to the field of metabolism and liver disease.

He is the current general director of CIC bioGUNE and CIC biomaGUNE, both located in the Basque Country, Spain. He also played a pivotal role in the establishment of OWL Metabolomics, taking part of the Scientific Advisory Committee since the company was founded.

Arun Sanyal, MD

Dr. Arun J. Sanyal, Professor of Medicine and Director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, currently serves as the Interim-Chair of the Division of Gastroenterology, Hepatology, and Nutrition at VCU/VCUHealth. His roles also include chairing the NIH NASH Clinical Research Network, the NIMBLE consortium, and the Liver Forum for NASH and fibrosis. His research primarily focuses on NAFLD and NASH, as well as complications of cirrhosis and end-stage liver disease.

With continuous NIH funding since 1995, Dr. Sanyal has contributed significantly to the field with over 350 peer-reviewed publications. He has held key national and global positions, including Chair of the Hepatobiliary Pathophysiology Study Section of the NIH. His outstanding contributions have earned him prestigious awards such as the Distinguished Mentorship Award from the American Gastroenterological Association and the Distinguished Achievement Award from the AASLD. Currently, he is involved in numerous clinical trials, leading several phase 2B and 3 trials for NASH and complications of end-stage liver disease.

https://intmed.vcu.edu/divisions/gastro/chair/